LDL-cholesterol levels in a series of HIV-infected patients;Colesterol ligado a lipoprotenas de baja densidad en una serie de pacientes con infeccin por el virus de la inmunodeficiencia humana

Medicina Clinica

Volumn 135, Issue 5, 2010, Pages 202-204

  Gallego, Marisa ^a   Palacios, Rosario ^a   Olalla, Julin ^b   Orihuela, Francisco ^c   Roldn, Juan ^d   Santos, Jess ^a   Grana, Mariela ^e  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

^c Hospital Carlos Haya   (Spain)

^d HOSPITAL DE ANTEQUERA   (Spain)

^e Hospital de la Serrana de Ronda   (Spain)

Author keywords

Dyslipidaemia; Human immunodeficiency virus; Statins; Target LDL Clevels

Indexed keywords

ANTIRETROVIRUS AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OBESITY; PREVALENCE; ADULT; BLOOD; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY;

ADULT; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 77953913466     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.10.052     Document Type: Article

References (16)

1. S. Lewington, G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, and J. Halsev Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 2007 1829 1839
2. N. Goldenberg, and C. Glueck Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk Vasc Health Risk Manag 5 2009 369 376
3. E. Van Ganse, T. Souchet, L. Laforest, P. Moulin, M. Bertrand, and P. Le Jeunne Ineffectiveness of lipid lowering therapy in primary care Br J Clin Pharmacol 59 2005 456 463 (Pubitemid 40523890)
4. M.J. Murphy, L. Wei, A.D. Watson, and T.M. MacDonald 'Real-life' reduction in cholesterol with statins, 1993 to 2002 Br J Clin Pharmacol 65 2008 587 592 (Pubitemid 351365136)
5. C. Chevalier, P. Giral, F. Chinaud, M. Carzon, D. Gartenlaub, and B. Blanchon Application of medical guidelines for the prescription of statins Rev Epidemiol Sante Publique 50 2002 463 473 (Pubitemid 35434735)
6. N. Friis-Moller, R. Weber, P. Reiss, R. Thibaut, O. Kirk, and A. D'Arminio Monforte Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study AIDS 17 2003 1179 1193 (Pubitemid 36667761)
7. J. Santos, R. Palacios, M. Gonzlez, J. Ruiz, and M. Mrquez Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Ntar Study) Int J STD AIDS 16 2005 677 680 (Pubitemid 41527350)
8. C. Jeric, H. Knobel, M.L. Sorli, M. Montero, A. Guelar, and J. Pedro-Botet Prevalence of cardiovascular risk factors in HIV-infected patients Rev Clin Esp 206 2006 556 559 (Pubitemid 46033686)
9. E. Bernal, M. Masi, S. Padilla, A. Martn-Hidalgo, and F. Gutirrez Sndrome metablico en pacientes infectados por el virus de la inmunodeficiencia humana en una cohorte del rea mediterrnea Med Clin (Barc) 128 2007 172 175 (Pubitemid 46382324)
10. A.G. Coloma Conde, M. lvarez Albarrn, A. Roca-Cusachs Coll, P. Domingo Pedrol, and M. Puig Campany Prevalencia de hipertensin arterial y perfil lipdico en pacientes con infeccin por el virus de la inmunodeficiencia humana Med Clin (Barc) 131 2008 681 684
11. M.P. Dub, J.H. Stein, J.A. Aberg, C.J. Fichtenbaum, J.G. Gerber, and K.T. Tashmina Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)infected adults receiving antiretroviral therapy: Recommendations of the HIV medicine association of the Infectious Disease Society of America and the adult AIDS clinical trials group Clin Infect Dis 37 2003 613 627
12. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment PanelIII) final report. Circulation. 2002;106:3143421.
13. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events Lancet 357 2001 995 1001
14. E. Van Ganse, L. Laforest, E. Alemao, G. Davies, S. Gutkin, and D. Yin Lipid-modifying therapy and attainment of cholesterol goals in Europe: The Return on Expenditure Achieved for Lipid Therapy (REALITY) study Curr Med Res Opin 21 2005 1389 1399 (Pubitemid 41368570)
15. P. Deambrosis, C. Saramin, G. Terrazzani, L. Scaldaferri, P. Debetto, and P. Giusti Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003 Eur J Clin Pharmacol 63 2007 197 203 (Pubitemid 46147062)
16. S. Perreault, L. Blais, D. Lamarre, A. Dragomir, D. Berbiche, and L. Lalonde Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention Br J Clin Pharmacol 59 2005 564 573 (Pubitemid 40632247)